Ambitious Amryt To File Butterfly Skin Drug Imminently
Irish Firm Eyes 2021 Launches For Filsuvez
The Dublin-based drugmaker, powered by climbing revenues of Lojuxta and Myalept, is preparing its launch teams for Filsuvez, which has the potential to become the first treatment approved for epidermolysis bullosa and the company is banking on speedy regulatory reviews.
You may also be interested in...
The US regulator is worried about deficiencies in the submission for Provention Bio’s high-profile therapy teplizumab for the prevention of type 1 diabetes that could significantly delay its review.
Sanofi is the latest drugmaker to announce a major initiative aimed at improving access to medicines in poorer countries, the type of move that should continue to lift the reputation of big pharma above the likes of big oil and big tobacco.
Phase III trials of a number of late-stage investigational therapies are expected to read out during the second quarter of 2021, according to new analysis from Informa Pharma’s product pipeline database Biomedtracker. Some of the Phase III data could be transforming for a few of the less grand players in the pharma sector and here Scrip picks out some of the highlights to look out for in the months ahead.